504095867 11/15/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 EPAS ID: PAT4142535 Stylesheet Version v1.2

 SUBMISSION TYPE:
 NEW ASSIGNMENT

 NATURE OF CONVEYANCE:
 ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
EVOTEC (UK) LTD.	11/04/2016

RECEIVING PARTY DATA

Name:	QUARTET MEDICINE INC.
Street Address:	400 TECHNOLOGY SQ.
Internal Address:	10TH FLOOR
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02139

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	15282000
PCT Number:	US1654657

CORRESPONDENCE DATA

Fax Number: (312)474-0448

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 312-474-6300

Email: docket@marshallip.com,lfrasher@marshallip.com

Correspondent Name: MARSHALL, GERSTEIN & BORUN LLP

Address Line 1: 233 SOUTH WACKER DRIVE

Address Line 2: SUITE 6300

Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER: 32297/40000A

NAME OF SUBMITTER: KELLY A. PLUMMER

SIGNATURE: /Kelly A. Plummer/

DATE SIGNED: 11/15/2016

Total Attachments: 1

source=40000a-evotec--quartet-assignment#page1.tif

PATENT 504095867 REEL: 040321 FRAME: 0229

ASSIGNMENT

This assignment agreement ("Assignment") is effective as of September 30, 2015 ("Effective Date") and entered into by and between Evotec (UK) Ltd. located at 114 Innovation Drive, Milton Park, Abingdon, OX14 4RZ Oxfordshire, United Kingdom ("Assignor") and Quartet Medicine, Inc. located at 400 Technology Sq, 10th floor, Cambridge, Massachusetts 02139 ("Assignee").

For good and valuable consideration, the receipt and sufficiency of which are agreed, Assignor hereby irrevocably sells, assigns and transfers to Assignee and its successors, assigns and legal representatives, Assignor's entire right, title and interest, both legal and equitable, in U.S. Patent Application Serial No. 15/282,000, filed September 30, 2016, International Application No. PCT/US16/54657, filed September 30, 2016, and U.S. Patent Application Serial No. 62/235,191, filed September 30, 2015, and to the inventions described therein and improvements thereof, all related patent applications throughout the world including those claiming priority thereto anywhere in the world, the right of priority, including without limitation to claim priority benefit of or to said patent applications, all continuations, divisionals and continuations-in-part of any of the foregoing, patents issuing from any of the foregoing, and reissues, reexaminations, extensions and foreign equivalents thereof and supplementary protection certificates allowed on any of the foregoing (collectively the "Patent Rights") for Assignee's own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; together with all income, royalties, damages or payments due or payable as of the Effective Date or thereafter, including, without limitation, all claims for damages by reason of past, present or future infringement or other unauthorized use of the Patent Rights, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

Upon the request of Assignee, the undersigned agrees to execute any and all documents and take actions reasonably requested to effectuate this assignment and Assignee's rights in the Patent Rights, including any oath or affidavit relating thereto, to cooperate to the best of the ability of the undersigned with Assignee in preparing and executing statements and giving and producing evidence in support of the Patent Rights, and to perform any and all acts reasonably requested by Assignee to obtain, enforce and defend the Patent Rights and vest all rights therein to Assignee as fully and entirely as the same would have been held and enjoyed by the undersigned if this Assignment had not been executed.

The parties execute and deliver this Assignment by their respective signatories below.

Evotec (UK) Ltd.	Quartet Medicine, Inc.
x H. Polywka	x school det will
Name: DR MARCIO POLYWKA	Name: Gerhard Koenig, Ph.D. Chief Executive Officer
Title: COO	Title: Quartet Medicine
Date: 4/11/2016	Date:
Witnesses:	Witnesses:
x aworth	
x Cleeci	× Office

PATENT REEL: 040321 FRAME: 0230

RECORDED: 11/15/2016